Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPIDIOLEX®/EPIDYOLEX® (cannabidiol), the first prescription, plant-derived cannabis-based medicine approved by the U.S. FDA for use in the U.S. and the European Commission for use in the European Union, is an oral solution which contains highly purifie...
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $7,200.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
Details : Jazz Pharmaceuticals adds third high-growth commercial franchise: Epidiolex® (cannabidiol) oral solution is a transformative treatment for childhood-onset epilepsy that provides a critical therapeutic option for refractory seizures.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : $7,200.0 million
May 05, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $7,200.0 million
Deal Type : Acquisition
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GW Pharmaceuticals has received European Commission (EC) approval for the type II variation application for Epidyolex (cannabidiol), as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) for patients two years of age and...
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 20, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $7,200.0 million
Deal Type : Acquisition
Details : With this acquisition, Jazz Pharma adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : $7,200.0 million
March 02, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Jazz Pharmaceuticals
Deal Size : $7,200.0 million
Deal Type : Acquisition
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study found that individuals treated with EPIDIOLEX 25 mg/kg/day or 50 mg/kg/day experienced a significantly greater reduction in TSC-associated seizures (48.6% for 25 mg/kg/day and 47.5% for 50 mg/kg/day) compared to placebo.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Australian Therapeutic Goods Administration (TGA) has approved EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 31, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
Details : Five new MS Spasticity Phase 3 trials are expected to commence in H2 2020 (2) and H1 2021 (3), any one of which the company believes could enable a NDA submission.
Product Name : Nabiximols
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has accepted for filing with Priority Review its recently submitted supplemental New Drug Application for the use of EPIDIOLEX CV to treat seizures in Tuberous Sclerosis Complex.
Product Name : Epidiolex
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Greenwich Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is a Phase 3, double-blind, parallel, placebo-controlled study that will evaluate the safety and efficacy of nabiximols for spasm frequency over a 12-week period and is expected to enroll 446 participants.
Product Name : Nabiximols
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 11, 2020
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
